Antibody shield for vulnerable patients: Real-World data shows promise
NCT ID NCT05439044
First seen Apr 22, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study followed over 4,200 immunocompromised patients who received monoclonal antibodies to prevent or treat severe COVID-19. Researchers tracked how many were hospitalized or died from the virus. The goal was to see how well these antibody treatments work in real-world settings for people at high risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOCOMPROMISED PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital
Paris, Île-de-France Region, 75014, France
Conditions
Explore the condition pages connected to this study.